Skip to content
Search AI Powered

Latest Stories

This New Agreement Between 23andMe and GlaxoSmithKline Pharmaceuticals Is Causing Major Concern Among Privacy Advocates

This New Agreement Between 23andMe and GlaxoSmithKline Pharmaceuticals Is Causing Major Concern Among Privacy Advocates

The future that TED Talks have long promised is one step closer to reality.

The future that TED Talkshavelongpromised is one step closer to reality, thanks to a new deal between pharmaceutical giant GlaxoSmithKline (GSK) and home DNA-testing kit service 23andMe.

The four-year agreement will grant GSK exclusive access to 23andMe’s database of genetic information, with the goal of developing new, targeted drugs and therapies. This isn’t the first time that 23andMe has offered its customers’ data to another organization for research, but those partnerships have previously been transparent. What does this new deal mean for genetic privacy and who will benefit from the partnership?


To privacy advocates,there’s little more alarming than the sale of genetic information. The data could be used by insurance companies to identify certain genetic markers as high-risk, leading to increased premiumseven decades after the test is performed. Law enforcement could subpoena the data from 23andMe (or any other genetic testing company) without informing the customers and without their consent. Thelaw surrounding questions of genetic privacy and ownership are in their infancy. And no genetic testing company canensure that your genetic information remains private.

But in this case, the most serious issue seems to be profit. 23andMe’s estimated 5 million customers can choose to opt out of having their DNA used in research. Those who don’t opt out have essentially donated their genome to science. But that munificence is one-sided: whatever drugs or treatments are developed using the customers’ genetic information will be sold by GSK or 23andMe for profit.

And there’s certainly profit to be made. Separate from this deal, GSK has invested $300 million in 23andMe. It’s a relative bargain for GSK, because 23andMe’s database is up to 10 times larger than other available databases, and its customers have already paid for partial sequencing — typically a major expense.

For its part, GSK is confident that the partnership will produce effective treatments, which will benefit patients across the world. To begin, they’re focusing on treatments for Parkinson’s disease based on a gene called LRRK2 that is mutated in some Parkinson’s patients.

“When you get a genetically validated target and you pursue it, it’s twice as likely to end up being a medicine,” said GSK chief science officer Hal Barron.

Previously, 23andMe had been carrying out some genetic research itself, in partnership with the National Institutes of Health (NIH)  and University of California, Los Angeles and University of Southern California.In those cases, customers could see a clear benefit in allowing research to be carried out on their genome. Just by allowing the company to use the material that the customer had already given, they felt like part of a larger solution.

“It’s one thing for NIH to ask people to donate their genome sequences for the higher good,” Peter Pitts, president of the Center for Medicine in the Public Interest, told NBC News. “But when two for-profit companies enter into an agreement where the jewel in the crown is your gene sequence and you are actually paying for the privilege of participating, I think that’s upside-down.”

More from News

Kid Rock
Todd Kirkland/Getty Images

Kid Rock Dragged After Donning A Truly Over-The-Top Outfit For His White House Visit

Singer Kid Rock was slammed for wearing a loud patriotic costume inside the Oval Office as Republican President Donald Trump signed an executive order on Monday against ticket scalping.

The rocker's outfit consisted of a red, white, and blue jacket emblazoned with two eagles facing each other above the American flag with the number 250, a nod to America's upcoming 250th anniversary, and white stars on his sleeves.

Keep ReadingShow less
Screenshot of Bill Cassidy
CNBC

MAGA Senator Just Said The Quiet Part Out Loud With Epic Freudian Slip About Medicare

Louisiana Republican Senator Bill Cassidy was widely mocked following his inconvenient slip of the tongue during a CNBC interview as he mused about finding ways to "cut" Medicare before quickly correcting himself.

The exchange occurred after host Rebecca Quick pressed Louisiana Republican and former physician Bill Cassidy on how his party intended to fund the “trillion-dollar tax cuts” sought by President Donald Trump.

Keep ReadingShow less
Screenshot of Tim Sheehy
CNN

GOP Senator Gets Blunt Reality Check After Comparing Trump Tariff 'Pain' To Home Renovation

Montana Republican Senator Tim Sheehy was criticized after he tried to compare the "short-term pain" of President Donald Trump's tariffs to home renovation, a claim so ridiculous that CNN's Kaitlan Collins quickly pushed back on the analogy.

Trump has repeatedly referred to April 2 as “Liberation Day,” pledging to impose tariffs—taxes on imports—to reduce U.S. reliance on foreign goods. He has framed these tariffs as “reciprocal,” aiming to match the duties other nations place on American exports.

Keep ReadingShow less
Susan Crawford; Elon Musk
Scott Olson/Getty Images (left and right)

Liberal Wisconsin Judge Calls Out Elon Musk In Victory Speech—And It's Everything

Liberal judge Susan Crawford called out billionaire Elon Musk in her victory speech after winning a seat on the Wisconsin Supreme Court, basking in successfully beating her Republican opponent Brad Schimel and ensuring that the nonpartisan court’s narrow 4-3 liberal majority remains intact despite Musk's efforts to sway the race.

Musk fueled the high-stakes race, having poured more than $20 million into supporting Schimel, according to state campaign records. That includes $3 million to the state Republican Party—$2 million of which was donated just last week. Due to state election laws, large contributions must be funneled through political parties before reaching candidates.

Keep ReadingShow less

People Describe The Worst 'Bonus' They've Ever Gotten At Work

Most of us have worked at one problematic workplace, with reasons ranging from toxic coworkers to terrible bosses to unlivable pay. Sometimes, it feels like a joke that the employees are even being paid at all!

But the biggest joke of all might be the end-of-year bonus, or lack thereof. They're at times so laughable, they take the cake for horrible work conditions, or are quite literally, a slice of cake.

Keep ReadingShow less